Do Healthcare CEOs Agree on Whether VBC and MA Actually Save Money?

Why It Matters

The outcome influences payer strategies, provider investments, and policy direction for U.S. healthcare spending.

Key Takeaways

• CEOs split on VBC and MA’s ability to lower costs
• Meucci cites fraud detection as VBC’s untapped savings source
• Gremminger argues MA remains pricier than traditional Medicare
• Direct contracting touted as simpler cost‑reduction alternative
• Payer pull‑back may force MA plans to innovate efficiently

Pulse Analysis

Value‑based care and Medicare Advantage have been championed as levers to rein in the United States’ spiraling health‑spending, yet senior leaders remain divided on their real‑world impact. Proponents such as Michael Meucci of Arcadia argue that VBC’s true value lies in its ability to surface fraud, waste and abuse through richer data analytics, while Jaewon Ryu of Risant Health sees population‑health management as a long‑term cost‑saver. Their optimism contrasts sharply with critics like Shawn Gremminger, who point to Medicare Advantage’s higher per‑beneficiary costs as evidence that the promised savings have not materialized.

The lack of consensus stems partly from measurement challenges. Many VBC contracts still focus on coding optimization and star ratings rather than direct cost outcomes, making it difficult to isolate genuine savings. Meanwhile, payer strategies are shifting; some insurers are trimming MA enrollment in less profitable markets, which could pressure remaining plans to operate more efficiently or adopt innovative technologies such as clinical AI. Yet, without transparent benchmarks, the industry struggles to prove that these efficiencies translate into lower overall expenditures.

For providers and employers, the debate signals a potential pivot toward alternative models like direct contracting, which Gremminger touts as a more transparent, dollars‑and‑cents approach. Policymakers will watch these dynamics closely, as the scalability of VBC and MA will affect future Medicare reforms and private‑sector investment decisions. Ultimately, the ability to demonstrate measurable cost reductions will determine whether VBC and MA remain flagship strategies or become footnotes in the broader quest for sustainable health‑care financing.